Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Vaccination and Alternative Immunotherapeutic Approaches against Emerging and (Re)emerging Neglected...
share announcement

Vaccination and Alternative Immunotherapeutic Approaches against Emerging and (Re)emerging Neglected Tropical Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1643

Special Issue Editors

Prof. Dr. Rosa A. Maldonado

E-Mail Website
Guest Editor
Department of Biological Sciences, University of Texas at El Paso, El Paso, TX, USA
Interests: drug and vaccine development for Chagas disease and leishmaniasis; ecology of disease; biomarkers for diagnostics; treatment follow-up
Prof. Dr. Walderez Ornelas Dutra

E-Mail Website
Guest Editor
Head of the Cell–Cell Interactions Laboratory, Department of Morphology, Federal University of Minas Gerais, Belo Horizonte, Brazil
Interests: immunoregulation of neglected tropical diseases, in particular Chagas disease, leishmaniasis and rheumatic heart disease; biomarkers of disease progression and severity and new immunotherapeutic approaches
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue aims to compile the latest advancements in the realm of innovative and enhanced vaccine formulations targeting tropical neglected pathogens. Cutting-edge immunotherapeutic approaches and mechanisms underlying the intricate host–pathogen interactions fall under the scope of this Special Issue. In addition, we encourage submissions addressing the mechanisms of action that exert influences upon the viability of the pathogens within both intermediary (invertebrate) and mammalian (comprising animal models and humans) hosts. Contributions encompassing clinical trial investigations are also invited.

Prof. Dr. Rosa A. Maldonado
Prof. Dr. Walderez Ornelas Dutra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antiviral vaccines
  • antiparasitic vaccines
  • antibacterial vaccines
  • immunotherapy of infectious diseases
  • adjuvants
  • immunological mechanisms
  • immunopathogenesis, innate and adaptive responses

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 2445 KiB  
Article
Immunogenicity and Neutralization of Recombinant Vaccine Candidates Expressing F and G Glycoproteins against Nipah Virus
by Seo Young Moon, Rochelle A. Flores, Min Su Yim, Heeji Lim, Seungyeon Kim, Seung Yun Lee, Yoo-kyoung Lee, Jae-Ouk Kim, Hyejin Park, Seong Eun Bae, In-Ohk Ouh and Woo H. Kim
Vaccines 2024, 12(9), 999; https://doi.org/10.3390/vaccines12090999 - 31 Aug 2024
Viewed by 872
Abstract
Nipah virus (NiV), of the Paramyxoviridae family, causes highly fatal infections in humans and is associated with severe neurological and respiratory diseases. Currently, no commercial vaccine is available for human use. Here, eight structure-based mammalian-expressed recombinant proteins harboring the NiV surface proteins, fusion [...] Read more.
Nipah virus (NiV), of the Paramyxoviridae family, causes highly fatal infections in humans and is associated with severe neurological and respiratory diseases. Currently, no commercial vaccine is available for human use. Here, eight structure-based mammalian-expressed recombinant proteins harboring the NiV surface proteins, fusion glycoprotein (F), and the major attachment glycoprotein (G) were produced. Specifically, prefusion NiV-F and/or NiV-G glycoproteins expressed in monomeric, multimeric (trimeric F and tetra G), or chimeric forms were evaluated for their properties as sub-unit vaccine candidates. The antigenicity of the recombinant NiV glycoproteins was evaluated in intramuscularly immunized mice, and the antibodies in serum were assessed. Predictably, all homologous immunizations exhibited immunogenicity, and neutralizing antibodies to VSV-luciferase-based pseudovirus expressing NiV-GF glycoproteins were found in all groups. Comparatively, neutralizing antibodies were highest in vaccines designed in their multimeric structures and administered as bivalent (GMYtet + GBDtet) and trivalent (Ftri + GMYtet + GBDtet). Additionally, while all adjuvants were able to elicit an immunogenic response in vaccinated groups, bivalent (GMYtet + GBDtet) and trivalent (Ftri + GMYtet + GBDtet) induced more potent neutralizing antibodies when administered with oil-in-water nano-emulsion adjuvant, AddaS03. For all experiments, the bivalent GMYtet + GBDtet was the most immunogenic vaccine candidate. Results from this study highlight the potential use of these mammalian-expressed recombinant NiV as vaccine candidates, deserving further exploration. Full article
(This article belongs to the Special Issue Vaccination and Alternative Immunotherapeutic Approaches against Emerging and (Re)emerging Neglected Tropical Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

41 pages, 862 KiB  
Review
Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis
by Andrea Lafleur, Stephane Daffis, Charles Mowbray and Byron Arana
Vaccines 2024, 12(10), 1179; https://doi.org/10.3390/vaccines12101179 - 17 Oct 2024
Viewed by 438
Abstract
Cutaneous leishmaniasis (CL), caused by protozoan parasites of the Leishmania genus, is prevalent in tropical and subtropical regions, with important morbidity, particularly in low- to middle-income countries. Current systemic treatments, including pentavalent antimonials and miltefosine, are associated with significant toxicity, reduced efficacy, and [...] Read more.
Cutaneous leishmaniasis (CL), caused by protozoan parasites of the Leishmania genus, is prevalent in tropical and subtropical regions, with important morbidity, particularly in low- to middle-income countries. Current systemic treatments, including pentavalent antimonials and miltefosine, are associated with significant toxicity, reduced efficacy, and are frequently ineffective in cases of severe or chronic CL. Immunotherapies leverage the immune system to combat microbial infection and offer a promising adjunct or alternative approach to the current standard of care for CL. However, the heterogeneous clinical presentation of CL, which is dependent on parasite species and host immunity, may require informed clinical intervention with immunotherapies. This review explores the clinical and immunological characteristics of CL, emphasising the current landscape of immunotherapies in in vivo models and clinical studies. Such immune-based interventions aim to modulate immune responses against Leishmania, with additive therapeutic effects enabling the efficacy of lower drug doses and decreasing the associated toxicity. Understanding the mechanisms that underlie immunotherapy for CL provides critical insights into developing safer and more effective treatments for this neglected tropical disease. Identifying suitable therapeutic candidates and establishing their safety and efficacy are essential steps in this process. However, the feasibility and utility of these treatments in resource-limited settings must also be considered, taking into account factors such as cost of production, temperature stability, and overall patient access. Full article
(This article belongs to the Special Issue Vaccination and Alternative Immunotherapeutic Approaches against Emerging and (Re)emerging Neglected Tropical Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop